Business Context and Reporting Period
This Form 8-K was filed by Nemus Bioscience, Inc. (noted as Skye Bioscience, Inc. in metadata) on November 1, 2018. The report details a specific financing event: a drawdown under a pre-existing credit agreement.
Key Financial Metrics and Transaction Details
- Drawdown Amount: $2,000,000.
- Facility Size: Revolving credit facility up to $20,000,000.
- Interest Rate: 7% per annum.
- Maturity Date: October 5, 2022.
- Security Status: Unsecured.
- Conversion Terms: Convertible into common stock at $0.40 per share (5,000,000 shares potential).
- Warrant Issuance: Warrant to purchase 2,500,000 shares at $0.50 per share, exercisable immediately, expiring in five years.
- Use of Proceeds: General corporate and working capital purposes.
Material Changes
The filing reports a new direct financial obligation of $2,000,000 incurred on November 1, 2018. This represents an increase in debt and potential future equity dilution due to the conversion feature and warrant issuance. The filing does not provide comparative financial data (revenue, profit, or cash flow) for prior periods.
Outlook, Risks, and Contingencies
- Default Risk: Upon an Event of Default, the entire outstanding principal and accrued interest become immediately due and payable.
- Dilution Risk: The lender (Emerald Health Sciences Inc.) holds the option to convert the debt into 5,000,000 shares and exercise warrants for an additional 2,500,000 shares.
- Regulatory Status: The securities were issued pursuant to Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, exempting them from registration.
Investor Verification Checklist
- Verify the current market price of Nemus Bioscience, Inc. common stock relative to the $0.40 conversion price and $0.50 warrant exercise price.
- Review the full text of the Credit Agreement (Exhibit 10.1) to understand specific "Event of Default" triggers.
- Confirm the company's current cash position and burn rate to assess the necessity of this drawdown.
- Check for any subsequent filings regarding further drawdowns or conversions under the $20,000,000 facility.